Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Azacitidine (Primary) ; Alemtuzumab; Fludarabine; Melphalan
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 05 Jun 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 19 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 07 Mar 2017 New trial record